Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2152W HIGH $6.95
Volume
612.37 K
Value Traded
3.41 M
Short % Float
7.13%
-5.04%Week
-24.57%1 Month
-42.86%3 Month
-52.52%6 Month
-93.21%5 Year
-83.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
249.93 M
EPS (TTM)
-1.47
P/E Ratio
-
Ent. Value
75.33 M
Total Shares
94.67 M
Float Shares
67.10 M
Insiders
29.12%
Institutions
42.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ZNTL Catalyst Timeline
Dated clinical, regulatory and corporate events for Zentalis Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zentalis Pharmaceuticals, Inc.
90Total events
6Upcoming
13Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Closed underwritten public offering of 26,450,000 shares at $3.50 per share, gross proceeds ~$92.6 million
◆Equity OfferingCorporate
Zentalis announces proposed underwritten public offering of common stock and pre-funded warrants
▲Type D MeetingAzenosertibFDA Meeting
Type D meeting with FDA on accelerated approval strategy
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲Enrollment CompleteAzenosertibTrial
Enrollment completed in DENALI Part 2a and 2b
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●Enrollment UpdateAzenosertibTrial
DENALI Part 2c currently enrolling
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●Trial InitiationAzenosertibTrial
Confirmatory ASPENOVA Phase 3 trial initiation expected Q2 2026
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▼Milestone PaymentAzenosertibCorporate
Milestone payment to Recurium IP Holdings due to ASPENOVA commencement
◆Poster PresentationAzenosertibPresentation
Azenosertib Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: Results From a Phase 1b Study
platinum-resistant ovarian cancersource ↗
▲Oral PresentationAzenosertibPresentation
MUIR Part 1 data presented at ASCO 2026
Platinum-resistant ovarian cancersource ↗
▲First Patient DosedAzenosertibTrial
First patient dosed in ASPENOVA Phase 3 confirmatory trial
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲First Patient DosedAzenosertibTrial
First patient dosed in Phase 3 ASPENOVA trial of azenosertib
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲First Patient DosedAzenosertibTrial
First patient dosed in Phase 3 ASPENOVA trial
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●AbstractAzenosertibPresentation
Abstract accepted for ASCO 2026: results from MUIR Part 1 (azenosertib + paclitaxel in PROC)
platinum-resistant ovarian cancersource ↗
◆Poster PresentationAzenosertibPresentation
Poster presentation: WEE1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer: Evaluating Single Agent and Combination Activity of Azenosertib in Preclinical Models
triple-negative breast cancersource ↗
◆Poster PresentationAzenosertibPresentation
Poster presentation: Real-World Treatment Patterns and Outcomes Reveal Distinct Clinical Trajectories of Patients with Cyclin E1-Positive Ovarian Cancer
Cyclin E1-positive ovarian cancersource ↗
◆Poster PresentationPresentation
Real-World Treatment Patterns and Outcomes Reveal Distinct Clinical Trajectories of Patients with Cyclin E1-Positive Ovarian Cancer
Ovarian Cancersource ↗
▲Interim AnalysisAzenosertibTrial
Planned interim analysis from DENALI Part 2a shows differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲Dose Finding UpdateAzenosertibTrial
Selection of 400mg QD 5:2 as optimal monotherapy dose for pivotal studies
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●Enrollment UpdateAzenosertibTrial
DENALI Part 2c cohort expansion initiated to include ~40 patients with prior taxane regimen
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
◆Trial InitiationAzenosertibTrial
ASPENOVA Phase 3 trial expected to initiate in Q2 2026
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲Dose Finding UpdateAzenosertibTrial
Pivotal dose 400mg QD 5:2 selected for azenosertib monotherapy based on DENALI Part 2a interim analysis
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●Poster PresentationAzenosertibPresentation
Poster at AACR 2026: azenosertib combinations induce complete tumor responses in ADC-resistant TNBC model
triple-negative breast cancersource ↗
▲Enrollment CompleteAzenosertibTrial
DENALI Part 2a enrollment completed
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
◆Oral PresentationPresentation
Zentalis management to participate in fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026
◆Dose Finding UpdateAzenosertibTrial
Dose confirmation for azenosertib monotherapy expected in 1H 2026
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲Trial InitiationAzenosertibTrial
Phase 3 ASPENOVA trial expected to initiate in 1H 2026
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲FDA Feedback ReceivedAzenosertibFDA Meeting
Aligned with FDA on randomized confirmatory Phase 3 trial design
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
●Quarterly UpdateCorporate
Cash runway guidance: $245.9M as of Dec 31, 2025, expected into late 2027
▲Topline ReadoutAzenosertibClinical Data
Phase 1b MUIR trial data for azenosertib plus paclitaxel in PROC
platinum-resistant ovarian cancersource ↗
◆Management ChangeCorporate
Appointment of James B. Bucher as Chief Legal Officer and Corporate Secretary
▲Enrollment CompleteAzenosertibTrial
Completed enrollment in DENALI Part 2a
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲Enrollment CompleteAzenosertibTrial
Completed enrollment in DENALI Part 2a
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
▲FDA Feedback ReceivedAzenosertibFDA Meeting
Aligned with FDA on Phase 3 ASPENOVA trial design
Cyclin E1-positive platinum-resistant ovarian cancersource ↗
◆Timing GuidanceAzenosertibPresentation
Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials
multiple (ovarian cancer, USC)source ↗
◆Oral PresentationAzenosertibPresentation
Investor call to review azenosertib monotherapy data and chemotherapy combination data presented at ASCO
advanced solid tumorssource ↗
▲Dose Finding UpdateAzenosertibTrial
Monotherapy RP2D established at 400 mg QD with 5/2 dosing schedule
advanced solid tumorssource ↗
▲Topline ReadoutAzenosertibClinical Data
ORR of 36.8% with intermittent dosing vs 19.2% with continuous dosing in ovarian cancer and USC subgroups
platinum-resistant ovarian cancer and uterine serous carcinomasource ↗
◆Enrollment UpdateAzenosertibTrial
New cohort of ongoing study enrolling patients at RP2D for PARP inhibitor-resistant and platinum-resistant ovarian cancer
PARP inhibitor-resistant and platinum-resistant ovarian cancersource ↗
▲Trial InitiationZN-d5Trial
Phase 1/2 study of ZN-d5 + azenosertib in R/R AML initiated
Acute Myeloid Leukemiasource ↗
▲First Patient DosedZN-c3Trial
First patient dosed in Phase 2 trial of ZN-c3 in USC
uterine serous carcinoma (USC)source ↗
▼Equity OfferingCorporate
Closed underwritten public offering raising ~$172.9 million gross proceeds
Past FDA Catalysts and PDUFA Decisions
How ZNTL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-01 | Azenosertib | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$89M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
Top 28%
Micro Cap(rank 185 of 657)
Percentile Rank
Zentalis Pharmaceuticals, Inc. carries a moderate pipeline score (45/100), with $1.2B risk-adjusted pipeline value, led by ZN-e4 in Carcinoma, Non-Small-Cell Lung (Phase 1), across $55B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZN-e4 Small moleculeCompletedNCT03446417 | Carcinoma, Non-Small-Cell Lung | Phase 1 | COMPLETED | 34 | Nov 15, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ZNTL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| azenosertib Fast TrackAccelerated | platinum-resistant ovarian cancer | Phase 2 | 2026-07-17 | long-term survival benefits demonstrated by azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancerRead More | Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WALTERS GROUP10% Owner | Buy | 4,335,000 17,844,973 held | $3.50 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZNTL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.6 % (50 %) | 6.85 M | 1.41 M |
ZNTL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZNTL ranks across every disease it competes in
Competitive Position is a premium feature
See how ZNTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZNTL News
ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced the grant of non-qualified stock options to three newly hired employees as part of its 2022 Employment Inducement Incentive Award Plan. This grant, totaling 62,000 shares, aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The options have a 10-year term and will vest over four years.
Read more →ZNTL▲ +9%on this news
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced its participation in two upcoming investor conferences, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The management team will discuss the company's innovative WEE1 inhibitor, azenosertib, aimed at treating ovarian cancer. This engagement underscores Zentalis's commitment to advancing its clinical oncology initiatives.
Read more →ZNTLZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Zentalis Pharmaceuticals has successfully closed an underwritten public offering, raising approximately $92.6 million through the sale of 26.45 million shares at $3.50 each. The proceeds will be utilized for clinical trials, regulatory filings, and other corporate purposes. The offering was well-received, with the underwriters fully exercising their option to purchase additional shares.
Read more →ZNTL▼ -14.2%on this newsshared move
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Zentalis Pharmaceuticals has announced the pricing of an underwritten public offering of 23 million shares at $3.50 each, aiming to raise around $80.5 million. The offering is set to close on August 17, 2026, and proceeds will be utilized for clinical trials, regulatory filings, and other corporate purposes. The company is advancing its WEE1 inhibitor, azenosertib, for ovarian cancer treatment.
Read more →ZNTL▼ -14.2%on this newsshared move
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Zentalis Pharmaceuticals announced a proposed underwritten public offering of its common stock, aiming to fund clinical trials and regulatory efforts for its WEE1 inhibitor, azenosertib, targeting ovarian cancer. The offering is contingent on market conditions, and the company plans to use the proceeds for various corporate purposes. Joint bookrunners for the offering include TD Cowen, Guggenheim Securities, and Oppenheimer & Co.
Read more →ZNTL▼ -15.6%on this news
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Zentalis Pharmaceuticals reported its Q2 2026 financial results, highlighting significant progress in the development of azenosertib, a potential first-in-class WEE1 inhibitor for ovarian cancer. The company completed enrollment in DENALI Parts 2a and 2b and expects topline results in the first half of 2027. With $174.6 million in cash, Zentalis is well-positioned to advance its clinical trials and regulatory strategies.
Read more →ZNTLZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Zentalis Pharmaceuticals announced two presentations at the ESMO Congress 2026, focusing on azenosertib's efficacy in treating platinum-resistant ovarian cancer. The rapid oral presentation will showcase overall survival data from the DENALI Part 1b study, while a trial-in-progress poster will detail the ASPENOVA Phase 3 study. These presentations underline Zentalis' commitment to advancing azenosertib as a treatment option for patients with high unmet needs.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Zentalis Pharmaceuticals announced the grant of non-qualified stock options for 191,000 shares to two new employees under its 2022 Employment Inducement Incentive Award Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The stock options will vest over four years, contingent on continued employment.
Read more →ZNTLZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
Zentalis Pharmaceuticals has appointed Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy. These appointments aim to bolster the company's commercial capabilities as it advances its investigational WEE1 inhibitor, azenosertib, through late-stage trials for Cyclin E1-positive platinum-resistant ovarian cancer. The company anticipates significant milestones in its registrational program.
Read more →ZNTL▲ +11.6%on this newsshared move
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals announced promising data from the Phase 1b MUIR trial for azenosertib combined with paclitaxel in treating platinum-resistant ovarian cancer. The trial showed a 39% overall response rate and a median progression-free survival of 7.3 months. The combination demonstrated a manageable safety profile with low rates of high-grade adverse events, indicating potential for broader application in ovarian cancer treatment.
Read more →ZNTLZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Zentalis Pharmaceuticals reported its financial results for Q1 2026, highlighting significant clinical progress with its investigational WEE1 inhibitor, azenosertib. The company selected a pivotal dose for its registration-intended trials and expects topline results from the DENALI Phase 2 trial by the end of 2026. Additionally, the ASPENOVA Phase 3 trial has commenced with the first patient dosed, aiming for full approval in Cyclin E1-positive ovarian cancer.
Read more →ZNTLZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial, dosing its first patient with azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial aims to compare azenosertib to standard chemotherapy and supports the company's strategy for accelerated approval. The study is crucial for addressing the significant unmet needs in this patient population.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Zentalis Pharmaceuticals announced the grant of stock options to a newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant, totaling 26,000 shares, adheres to Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $4.09 per share. The options will vest over four years, contingent on the employee's continued service.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced the grant of 26,000 stock options to a new employee under its 2022 Employment Inducement Incentive Award Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent to support its ongoing development of the WEE1 inhibitor azenosertib for ovarian cancer. The options have a 10-year term and will vest over four years.
Read more →ZNTL▼ -7.6%on this news· ran to -24% by day 3
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Zentalis Pharmaceuticals announced promising preclinical data on azenosertib, a WEE1 inhibitor, in triple-negative breast cancer (TNBC) and highlighted the significant unmet needs in Cyclin E1-positive ovarian cancer patients. The data will be presented at the AACR Annual Meeting 2026, showcasing azenosertib's potential to enhance treatment outcomes. The findings support expanding the drug's application beyond ovarian cancer.
Read more →ZNTL▲ +60.1%on this news· ran to +139% by day 1
zntlcorporateprese Corporate Presentation April 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. ("we," "us," "our," "Zentalis" or the "Company") cautions that this presentation (including oral commentary that accompan
Zentalis Pharmaceuticals, Inc. presented details about its future plans for azenosertib, an investigational drug, including the anticipated momentum in its development program throughout 2026. The presentation highlighted the completion of enrollment in the DENALI Part 2a trial and alignment with FDA on the Phase 3 ASPENOVA trial design. Zentalis has a robust financial foundation with $245.9M in cash as of December 31, 2025. However, the company also acknowledged challenges including the potential for serious side effects and the need for additional funding.
Read more →ZNTL▲ +60.1%on this news· ran to +139% by day 1
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has selected 400mg QD 5:2 as the optimal monotherapy dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer based on interim analysis from DENALI Part 2a. This dose will be utilized in the ongoing DENALI Phase 2 and ASPENOVA Phase 3 trials. The company is also preparing for commercialization and expanding its clinical pipeline.
Read more →About Zentalis Pharmaceuticals, Inc.
Headquarters10275 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next ZNTL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime